The Japanese herbal medicine Hangeshashinto enhances oral keratinocyte migration to facilitate healing of chemotherapy-induced oral ulcerative mucositis.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
17 01 2020
Historique:
received: 16 07 2019
accepted: 19 12 2019
entrez: 19 1 2020
pubmed: 19 1 2020
medline: 20 11 2020
Statut: epublish

Résumé

Chemotherapy often induces oral ulcerative mucositis (OUM) in patients with cancer, characterized by severe painful inflammation. Mouth-washing with the Japanese herbal medicine hangeshashinto (HST) ameliorates chemotherapy-induced OUM in patients with colorectal cancer. Previously, we demonstrated that HST decreased interleukin 1β-induced prostaglandin E2 production in human oral keratinocytes (HOKs) and OUM-induced mechanical or spontaneous pain in rats. However, HST effects on tissue repair functions in HOKs remain unclear. Here, we examined the effects of HST on scratch-induced wound healing in vitro and in vivo. In vitro, HST enhanced wound healing mainly through scratch-induced HOK migration. Screening of the seven constituent medicinal herbs and their major components revealed that Scutellaria root, processed ginger, and Glycyrrhiza components mainly induced the scratch-induced HOK migration. Pharmacokinetic analyses indicated that the active ingredient concentrations in rat plasma following oral HST administration were below the effective doses for HOK migration, suggesting direct effects of HST in OUM. Mitogen-activated protein kinase and C-X-C chemokine receptor 4 inhibitors significantly suppressed HST-induced HOK migration. Moreover, HST enhanced tissue repair in our OUM rat model. Thus, HST likely enhanced OUM tissue repair through oral keratinocyte migration upon MAPK and CXCR4 activation and may be useful in patients with cancer-associated OUM.

Identifiants

pubmed: 31953420
doi: 10.1038/s41598-019-57192-2
pii: 10.1038/s41598-019-57192-2
pmc: PMC6969174
doi:

Substances chimiques

Antineoplastic Agents 0
CXCR4 protein, human 0
Drugs, Chinese Herbal 0
Receptors, CXCR4 0
hange-shashinto 0
Mitogen-Activated Protein Kinase Kinases EC 2.7.12.2

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

625

Commentaires et corrections

Type : ErratumIn

Références

Curr Pharm Des. 2012;18(31):4839-53
pubmed: 22632864
Cancer Chemother Pharmacol. 2003 May;51(5):403-6
pubmed: 12687289
Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):72-8
pubmed: 9726096
World J Oncol. 2010 Dec;1(6):232-235
pubmed: 29147213
Arch Oral Biol. 2016 Jun;66:30-7
pubmed: 26878477
Radiother Oncol. 1983 Nov;1(2):159-65
pubmed: 6680220
Microbiol Immunol. 2000;44(2):135-41
pubmed: 10803500
J Natl Compr Canc Netw. 2008 Jan;6 Suppl 1:S1-21; quiz S22-4
pubmed: 18289497
Support Care Cancer. 2006 Jun;14(6):505-15
pubmed: 16601950
Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):103-9
pubmed: 9726101
Radiother Oncol. 2003 Mar;66(3):253-62
pubmed: 12742264
Integr Cancer Ther. 2014 Sep;13(5):435-45
pubmed: 24501112
Cell Cycle. 2009 Sep 15;8(18):2975-83
pubmed: 19713744
Odontology. 2016 May;104(2):152-62
pubmed: 25649126
Oral Dis. 2010 Oct;16(7):597-600
pubmed: 20846150
Core Evid. 2010 Jun 15;4:199-205
pubmed: 20694076
Neurosci Lett. 2016 Mar 11;616:57-64
pubmed: 26827717
Jpn J Cancer Res. 1995 Oct;86(10):978-84
pubmed: 7493918
Pain. 2016 May;157(5):1004-1020
pubmed: 26808144
Oral Oncol. 1998 Jan;34(1):39-43
pubmed: 9659518
Evid Based Complement Alternat Med. 2015;2015:512947
pubmed: 26170876
J Cell Physiol. 2009 Oct;221(1):204-12
pubmed: 19496172
Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000 Jul;90(1):39-47
pubmed: 10884634
Cancer Res. 2005 Nov 1;65(21):9891-8
pubmed: 16267013
Cancer. 2014 May 15;120(10):1453-61
pubmed: 24615748
Stem Cells Dev. 2013 Sep 1;22(17):2384-93
pubmed: 23544621
Mol Cancer Ther. 2007 Aug;6(8):2319-27
pubmed: 17699727
Cancer Chemother Pharmacol. 2015 Jul;76(1):97-103
pubmed: 25983022
Endocrinology. 2007 May;148(5):2317-25
pubmed: 17255201
In Vitro Cell Dev Biol Anim. 2015 Jan;51(1):92-101
pubmed: 25148824
Int J Oncol. 2018 Aug;53(2):750-760
pubmed: 29749481
Cancer. 2003 Oct 1;98(7):1531-9
pubmed: 14508842
Curr Pharm Des. 2016;22(15):2270-8
pubmed: 26891806
Surgery. 2018 Mar 22;:
pubmed: 29576309
J Clin Oncol. 1995 Jan;13(1):210-21
pubmed: 7799022
Int J Radiat Oncol Biol Phys. 2002 Mar 15;52(4):911-7
pubmed: 11958883
Semin Oncol Nurs. 2004 Feb;20(1):11-5
pubmed: 15038512
Oncol Nurs Forum. 1993 Nov-Dec;20(10):1493-502
pubmed: 8278277
J Radiat Res. 2015 Jul;56(4):669-77
pubmed: 25883171
Pharmacol Res. 2017 Mar;117:288-302
pubmed: 28043879
Eur J Immunol. 2007 Feb;37(2):338-50
pubmed: 17274000
Mol Carcinog. 2015 Oct;54(10):1132-46
pubmed: 24962868
J Support Oncol. 2007 May;5(5):231-5
pubmed: 17564153
Head Neck. 2005 May;27(5):421-8
pubmed: 15782422
J Clin Pediatr Dent. 2007 Spring;31(3):167-70
pubmed: 17550040
Support Care Cancer. 2007 Apr;15(4):427-40
pubmed: 17131132
Cancer. 2006 Jan 15;106(2):329-36
pubmed: 16342066
Mol Cancer Ther. 2007 Nov;6(11):3039-48
pubmed: 18025287
J Biol Chem. 2002 Dec 20;277(51):49212-9
pubmed: 12370187
Int J Radiat Oncol Biol Phys. 2007 Jul 15;68(4):1110-20
pubmed: 17398022
Am J Rhinol Allergy. 2009 Jul-Aug;23(4):385-91
pubmed: 19671252

Auteurs

Kanako Miyano (K)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.

Moeko Eto (M)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, 278-8510, Japan.

Suzuro Hitomi (S)

Division of Physiology, Kyushu Dental University, Fukuoka, 803-8580, Japan.

Takashi Matsumoto (T)

Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, 300-1192, Japan.

Seiya Hasegawa (S)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Department of Medicinal Chemistry, School of Pharmacy, Kitasato University, Tokyo, 108-8641, Japan.

Ayane Hirano (A)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Department of Medicinal Chemistry, School of Pharmacy, Kitasato University, Tokyo, 108-8641, Japan.

Kaori Nagabuchi (K)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Department of Medicinal Chemistry, School of Pharmacy, Kitasato University, Tokyo, 108-8641, Japan.

Noriho Asai (N)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.
Department of Medicinal Chemistry, School of Pharmacy, Kitasato University, Tokyo, 108-8641, Japan.

Miaki Uzu (M)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.

Miki Nonaka (M)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan.

Yuji Omiya (Y)

Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, 300-1192, Japan.

Atsushi Kaneko (A)

Tsumura Kampo Research Laboratories, Tsumura & Co., Ibaraki, 300-1192, Japan.

Kentaro Ono (K)

Division of Physiology, Kyushu Dental University, Fukuoka, 803-8580, Japan.

Hideaki Fujii (H)

Department of Medicinal Chemistry, School of Pharmacy, Kitasato University, Tokyo, 108-8641, Japan.

Yoshikazu Higami (Y)

Laboratory of Molecular Pathology and Metabolic Disease, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Chiba, 278-8510, Japan.
Translational Research Center, Research Institute of Science and Technology, Tokyo University of Science, Chiba, 278-8510, Japan.

Toru Kono (T)

Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, Hokkaido, Japan.

Yasuhito Uezono (Y)

Division of Cancer Pathophysiology, National Cancer Center Research Institute, Tokyo, 104-0045, Japan. yuezono@ncc.go.jp.
Division of Supportive Care Research, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Tokyo, 104-0045, Japan. yuezono@ncc.go.jp.
Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center Hospital, Tokyo, 104-0045, Japan. yuezono@ncc.go.jp.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH